Dr. Reddy's Laboratories Share Price

₹ 1,385.00

+₹15.00 (1.09%)
1D
Last updated 09 Nov, 2026, 15:51 IST
NSE: DRREDDY
|
Pharmaceuticals

Dr. Reddy's Laboratories Share Price Today

As of 10 Nov 2026, Dr. Reddy's Laboratories share price is ₹1,385.00. The stock opened at ₹1,375.00, compared to its previous close of ₹1,370.00. During today's trading session, Dr. Reddy's Laboratories share price moved in the range of ₹1,369.30 to ₹1,390.30, with an average price of ₹1,379.80 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,101.00 and a high of ₹1,414.90. On the performance front, Dr. Reddy's Laboratories share price has increased by 7.04% over the last six months and is up 14.90% on a year-on-year basis.

Share price over the last 1 day rose from 1369.70 to 1385.00, ranging between 1369.70 and 1389.70.
₹1,369.30
1.09% up today
₹1,390.30
1D LOW
1D HIGH

Dr. Reddy's Laboratories Stock Insights

Latest Earning
Op Profit TrendUp by 121.87% QoQ
Latest Earning
Net Profit TrendUp by 109.64% QoQ
Latest Earning
Revenue TrendUp by 4.73% QoQ
Stock Performance
OutperformingBeat Nifty by 3.32 % in last 1 month
Shareholding Pattern
DIIDII decreased stake by 4.52%
Shareholding Pattern
FIIFII decreased stake by 2.13%
Dr. Reddy's Laboratories stock performance
Open₹1,375.00
High₹1,390.30
Low₹1,369.30
Prev. close₹1,370.00
Dr. Reddy's Laboratories trading activity
Volume17,88,177
Average traded price₹1,381.79
Last traded time03:51:36 09 Nov
Last traded quantity5
Circuit
L
H
₹1,338.70
₹1,421.50
52-week
L
H
₹1,101.00
₹1,414.90
Mkt Cap Cr
1,14,532.44
P/E
41.43
P/B
2.95
ROA
4.79%
ROE
7.21%
ROCE
8.58%
Quick Ratio
1.35
EV/EBITDA
19.35

Based on fundamentals, this stock's

Performance: 5 out of 5, Excellent
Performance
Excellent
Dr Reddy's Labs outperforming all market indices
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Dr Reddy's Labs appears overvalued compared to its peers
Earnings: 4 out of 5, Good
Earnings
Good
Dr Reddy's Labs revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,59,496.6441.825.159.61%13.79%18.65%2.3123.35
Divis Laboratories2,94,145.8287.4716.3413.32%15.32%19.56%3.562.27
Torrent Pharmaceuticals1,81,473.5086.469.884.7%11.42%11.37%0.7534.53
Laurus Labs1,28,054.0096.1121.1311.58%22.11%20.91%0.6853.3
Zydus Lifesciences1,19,700.4627.824.37.63%15.1%14.86%0.9116.0
Cipla1,13,988.9739.953.226.6%8.18%10.8%2.521.52
Mankind Pharma1,04,913.4547.036.057.82%12.76%14.68%0.7425.47
Aurobindo Pharma1,03,395.4126.062.646.46%10.13%12.76%1.1512.49
Lupin91,229.9517.473.7913.08%21.65%24.54%1.4210.19
Glenmark Pharma73,237.3050.476.536.78%18.07%19.86%1.2326.52

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Dr. Reddy's Laboratories Company Background

ISIN
INE089A01031
Sector Market Cap
₹ 114,532.44 Cr

Dr. Reddy's Laboratories is an Indian pharmaceutical company that was founded in 1984 by Kallam Anji Reddy. Headquartered in Hyderabad, the company produces over 190 medications and over 60 active pharmaceutical ingredients (APIs).

The market capitalisation of Dr. Reddy's Laboratories Limited was ₹97,400 crore as of January 4, 2024. The share price of Dr. Reddy's has gained over 10% in the last three years

Business Operations

Dr. Reddy's Laboratories has been an active player in the pharmaceutical sector for more than 20 years. Its expertise lies in Active Pharmaceutical Ingredients (API), boasting a diverse portfolio. They specialise in manufacturing generic medicines with operations in India, Russia, US and Germany.

The company also engages in proprietary products, biologics business and unique formulations conducted primarily in the US. It has introduced Grafeel (Filgrastim), a drug used to fight infections after chemotherapy, and Reditux (Rituximab), an ant-cancer drug.

Dr. Reddy's produces a diverse range of intricate APIs and holds over 1,150 drug master files covering key therapy areas like oncology, cardiovascular, central nervous system and anti-diabetes. With 22 manufacturing facilities worldwide, the company ensures top-quality output and timely supply to markets. Its expertise in Active Pharmaceutical Ingredients (API) spans 8 manufacturing units globally.

The company’s largest manufacturing facility is located in Bachupally, Hyderabad. As of FY22, it has filed 1,071 patents and published over 1,000 papers.

Central to its R&D excellence is the Integrated Product Development Organisation (IPDO) situated in Hyderabad. This extensive campus hosts multiple laboratories, including the latest addition, a nutraceutical R&D centre. These cutting-edge labs are powered by a diverse team of scientists recruited from leading institutions worldwide.

The dedicated efforts of Dr. Reddy's in product development support a portfolio exceeding 1,000 products. The pharma giant has an R&D team comprising over 150 doctorates.

The company is focused on research and has a strong team of over 3,000 scientists in 8 R&D facilities. As of March 31, 2023, Dr. Reddy's is powered by a workforce of 25,498 permanent employees and workers in 74 countries.

The business of Dr. Reddy's Laboratories in branded generics thrives not only in India but also in emerging markets globally. Its branded products reach over 30 countries, spanning Asia, Africa, Australia, New Zealand, Russia, Romania, China and Latin America.

The company's growth rate has doubled in the past four years. It has reached a prominent position in crucial therapy areas like oncology, gastroenterology, allergy, diabetes and pain management. Within its Indian operations, it structures its business according to therapies, managing over 300 brands. Its extensive reach to healthcare professionals is facilitated by a field force comprising approximately 7,500 members.

Dr. Reddy's Laboratories Financial Highlights

  • Revenue: Dr. Reddy's Laboratories reported revenue of ₹35,058.60 crore in FY26 vs ₹33,741.20 crore in FY25. It showed an increase of 3.90% on a yearly basis.
  • Operating Profit: Dr. Reddy's Laboratories reported an operating profit of ₹5,392.70 crore in FY26 vs ₹7,679.50 crore in FY25. It showed a decrease of 29.78% on a year-on-year basis.
  • Net Profit: Dr. Reddy's Laboratories reported a net profit of ₹4,157.60 crore in FY26 vs ₹5,725.20 crore in FY25. It showed a decrease of 27.38% on a yearly basis.

Dr. Reddy's Laboratories Quarterly Result Highlights

  • Dr. Reddy's Laboratories reported revenue of ₹8,854.00 crore in Sep 2026, compared with ₹8,454.50 crore in Jun 2026, representing an increase of 4.73% on a quarter-on-quarter (QoQ) basis.
  • Dr. Reddy's Laboratories reported an operating profit of ₹1,227.60 crore in Sep 2026, compared with ₹553.30 crore in Jun 2026, representing an increase of 121.87% on a quarter-on-quarter (QoQ) basis.
  • Dr. Reddy's Laboratories reported a profit of ₹913.20 crore in Sep 2026, compared with ₹435.60 crore in Jun 2026, reflecting an increase of 109.64% on a QoQ basis.
  • The earnings per share (EPS) of Dr. Reddy's Laboratories stood at ₹50.41 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
26.63%
FII
31.39%
Other DII
17.74%
Retail and other
10.10%
Mutual funds
14.14%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 202533.20%
Mar 202633.08%
Jun 202632.07%
Sep 202631.39%

Dr. Reddy's Laboratories Investment Returns

1 day
+1.09%
1 week
+1.22%
1 month
+15.71%
1 year
+14.90%
3 years
+26.88%
5 years
+44.50%

Dr. Reddy's Laboratories Share Price History

Dr. Reddy's Laboratories share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
09 Nov 26
₹1,375.00 / ₹1,385.00
+1.09%
08 Nov 26
₹1,374.20 / ₹1,370.00
-0.22%
06 Nov 26
₹1,358.40 / ₹1,373.00
+0.51%
05 Nov 26
₹1,377.00 / ₹1,366.00
-0.58%
Show more

Dr. Reddy's Laboratories Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹33,700.20₹32,643.90₹28,011.10₹24,669.70
Other Income₹1,358.40₹1,097.30₹894.30₹1,055.50
Total Revenue₹35,058.60₹33,741.20₹28,905.40₹25,725.20
Total Expenses₹29,679.30₹26,083.40₹21,719.10₹19,713.70
Profit Before Tax₹5,392.70₹7,679.50₹7,201.00₹6,048.50
Tax₹1,235.10₹1,954.30₹1,623.10₹1,541.20
Profit After Tax₹4,157.60₹5,725.20₹5,577.90₹4,507.30
EPS - Basic₹50.41₹67.89₹67.04₹271.47
EPS - Diluted₹50.35₹67.79₹66.92₹270.90

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹5,392.70₹7,679.50₹7,201.00₹6,048.50
Income before WC changes₹8,100.90₹9,641.00₹8,566.20₹7,744.40
Change in Assets-₹1,532.30-₹2,303.60-₹2,649.90-₹840.60
Change in Liabilities₹457.70-₹695.30₹631.70₹55.10
Change in WC-₹1,074.60-₹2,998.90-₹2,018.20-₹785.50
Cash flow from Operations₹5,673.70₹4,642.80₹4,543.30₹5,887.50
Cash flow from Investing-₹6,549.30-₹5,807.70-₹4,028.30-₹4,137.30
Cash flow from Financing₹829.00₹1,891.10-₹376.30-₹2,686.10
Total Cash Flow-₹46.60₹726.20₹138.70-₹935.90
Cash (Start of the year)₹1,459.30₹710.70₹577.90₹1,485.20
Cash (End of the year)₹1,536.80₹1,459.30₹710.70₹577.90

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹27,944.10₹24,408.50₹14,058.50₹11,859.60
Current Assets₹30,179.30₹25,018.10₹24,805.30₹20,425.50
Total Assets₹58,123.40₹49,426.60₹38,863.80₹32,285.10
Current Liabilities₹16,747.40₹13,033.80₹9,588.00₹8,572.10
Net Current Asset₹13,431.90₹11,984.30₹15,217.30₹11,853.40
Non-Current Liabilities₹3,145.10₹2,465.40₹1,021.00₹426.90
Equity Capital₹38,230.90₹33,927.40₹28,254.80₹23,286.10
Total Equity & Liabilities₹58,123.40₹49,426.60₹38,863.80₹32,285.10

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹20,532.80₹23,115.40₹19,483.80₹16,962.50
Other Income₹1,689.60₹1,003.40₹862.30₹591.30
Total Revenue₹22,222.40₹24,118.80₹20,346.10₹17,553.80
Total Expenses₹17,971.10₹16,882.90₹14,554.80₹13,687.80
Profit Before Tax₹4,251.30₹7,235.90₹5,791.30₹3,866.00
Tax₹1,031.60₹1,886.50₹1,449.30₹1,253.20
Profit After Tax₹3,219.70₹5,349.40₹4,342.00₹2,612.80
EPS - Basic₹38.68₹64.22₹52.19₹157.37
EPS - Diluted₹38.64₹64.13₹52.09₹157.03

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹4,251.30₹7,235.90₹5,791.30₹3,866.00
Income before WC changes₹4,742.30₹8,050.30₹6,393.30₹4,911.80
Change in Assets₹999.10-₹2,179.10-₹1,558.00₹556.80
Change in Liabilities-₹133.60-₹59.80-₹66.10₹367.00
Change in WC₹865.50-₹2,238.90-₹1,624.10₹923.80
Cash flow from Operations₹4,660.50₹4,225.00₹3,449.70₹5,052.90
Cash flow from Investing-₹5,784.70-₹5,697.60-₹3,430.30-₹3,447.60
Cash flow from Financing₹1,116.80₹1,590.70₹68.10-₹2,696.90
Total Cash Flow-₹7.40₹118.10₹87.50-₹1,091.60
Cash (Start of the year)₹319.70₹201.40₹112.30₹1,159.50
Cash (End of the year)₹337.50₹319.70₹201.40₹112.30

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹25,078.90₹21,787.90₹12,543.40₹11,586.50
Current Assets₹18,523.20₹16,503.00₹17,815.90₹13,788.30
Total Assets₹43,602.10₹38,290.90₹30,359.30₹25,374.80
Current Liabilities₹11,142.50₹8,651.80₹5,538.10₹4,439.70
Net Current Asset₹7,380.70₹7,851.20₹12,277.80₹9,348.60
Non-Current Liabilities₹1,094.00₹782.50₹580.40₹460.90
Equity Capital₹31,365.60₹28,856.60₹24,240.80₹20,474.20
Total Equity & Liabilities₹43,602.10₹38,290.90₹30,359.30₹25,374.80
* All values are in INR Crore
Dr. Reddy's Laboratories market depth
Bid quantityBid priceAsk priceAsk quantity
001385892
0000
0000
0000
0000
Total bid quantity0
Total ask quantity892
Dr. Reddy's Laboratories technical summary
Bearish indicators4
Neutral indicators2
Bullish indicators2
OverallSlightly Bearish
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
72.59
Bullish
ATR (14)
29.9
Neutral
STOCH(9,6)
82.14
Bearish
STOCH RSI (14)
84.55
Bearish
ADX(9)
48.21
Bearish
UO(9)
58.55
Neutral
ROC(12)
10.57
Bullish
WillR(14)
-8.71
Bearish
Period
Simple value
Exponential vaue
5D
1370.26
1365.23
10D
1353.57
1346.21
20D
1296.97
1310.08
50D
1228.03
1259.16
100D
1229.59
1244.98
Volume trend — traded volume by day
9 Nov17L
8 Nov0L
6 Nov13L
5 Nov18L
4 Nov18L
3 Nov19L
Average14L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Dr. Reddy's Laboratories
Pharmaceuticals
Add Stock
Add Another

Dr. Reddy's Laboratories Returns Calculator

Ex-date: 10 Jul 2026

Dr. Reddy's Laboratories Latest News

6 days ago
Dr Reddy’s secures tentative US FDA approval for generic injectable HIV prevention drug; stock rises 1%
2 weeks ago
Top gainers and losers, Oct 26: Dr. Reddy’s rallies 7%, JSW Steel gains 6%, Shriram Finance falls 5%; check list
2 weeks ago
LTTS, Dr. Reddy’s, Apollo Micro Systems among buzzing stocks as SENSEX, NIFTY50 trade flat in noon deals
2 weeks ago
Stocks to watch, Oct 26: Senco Gold, Infosys, Coforge, Paytm, ITC Hotels, JBM Auto, JSW Steel, Dr Reddy's
3 weeks ago
Max Healthcare, Apollo Hospitals, Sun Pharma, Dr Reddy’s: Stocks trade lower as NPPA caps cancer drug margins
3 weeks ago
Dr Reddy’s, Torrent Pharma, Zydus Life: Pharma stocks to post resilient growth in Q2 earnings despite pricing headwinds
4 weeks ago
Top gainers and losers, October 12: Apollo Hospitals, ITC fall 3%; Dr. Reddy’s, Bajaj Auto jump 3%
1 month ago
Sun Pharma, Dr Reddy’s, Max Healthcare: Pharma, hospital stocks rise up to 6% amid anti-cancer drug margin cap on MRP
1 month ago
NIFTY50 lost 6% in September: Coal India, Adani Ports, Dr Reddy’s gained up to 13% in the period; here's why
1 month ago
Mankind, Dr Reddy, Gland Pharma, others lift Nifty Pharma up over 1% as US exempts certain drugs from 100% tariffs
Showing news item 1 of 10

Top Gainers

CHEMPLASTS Share Price
₹237.83
+24.42 (+11.44%)
DATAPATTNS Share Price
₹4025.00
+321 (+8.67%)
QUESS Share Price
₹345.70
+27.15 (+8.52%)
SPARC Share Price
₹210.80
+13.77 (+6.99%)
GLAXO Share Price
₹2710.00
+170.4 (+6.71%)
See more

Top Losers

RRKABEL Share Price
₹1969.40
-146 (-6.9%)
FINCABLES Share Price
₹1232.40
-76.6 (-5.85%)
ALIVUS Share Price
₹1474.40
-84.3 (-5.41%)
TTML Share Price
₹39.33
-2.18 (-5.25%)
STLTECH Share Price
₹670.95
-35.3 (-5%)
See more

Dr. Reddy's Laboratories Share Price FAQs

Please be aware that Dr. Reddy's Laboratories stock prices are subject to continuous fluctuations due to various factors.